Gilead Says Hold on MDS and AML Magrolimab Studies Lifted

Gilead reported that the U.S. FDA lifted the partial clinical hold placed on studies evaluating its investigational agent magrolimab in combination with azacitidine.

• FDA removed the partial clinical hold after a review of the comprehensive safety data from each trial
• Enrollment in the U.S. can resume for the studies immediately

NOTE

• Gilead Sciences Inc. shares were little changed in postmarket trading as of 4:15 p.m. New York time
  • The average 12-month price target of $72.20 is 16.7% above the current price
  • 15 holds, 14 buys, 1 sells

To contact the reporter on this story:
Molly Kissler in New York at ...